Leqvio (Inclisiran) Legal and Patent Challenges

FDA Approval Timeline and Regulatory Path

Inclisiran received its first regulatory green light from the European Medicines Agency in December 2020 under the brand name Leqvio, approved for adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet. The FDA followed one year later, granting approval on December 22, 2021, for adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering (FDA approval letter).

The approval rested primarily on the ORION Phase III program. ORION-10 (N=1,561) and ORION-11 (N=1,617), published together in the New England Journal of Medicine in March 2020, demonstrated that inclisiran 284 mg reduced LDL-C by 52.3% and 49.9%, respectively, versus placebo at Day 510 (Ray et al., NEJM 2020). The pooled safety profile showed injection-site reactions in 5% of inclisiran-treated patients versus 0.7% on placebo. No hepatotoxicity signals or thrombocytopenia clusters emerged during the trial period.

One notable regulatory detail: the FDA's initial review included a Refuse to File letter in 2020, citing deficiencies in the original BLA submission. Novartis resubmitted with additional chemistry, manufacturing, and controls (CMC) data, which delayed the approval by roughly 10 months relative to the EMA. That gap created a window in which European prescribers gained clinical experience before U.S. providers could access the drug.

Intellectual Property Disputes and the Alnylam License

The patent story behind Leqvio is tangled. Novartis acquired global rights to inclisiran through its $9.7 billion acquisition of The Medicines Company in January 2020. The Medicines Company had previously licensed the drug from Alnylam Pharmaceuticals, which developed the GalNAc (N-acetylgalactosamine) conjugate delivery platform that enables liver-targeted siRNA therapeutics.

Alnylam's GalNAc-siRNA platform is protected by a broad portfolio of composition-of-matter, formulation, and method-of-use patents. Some of these patents are shared with or licensed from academic institutions, including the Max Planck Institute and the University of British Columbia. This layered ownership structure has generated disputes over royalty obligations and sublicensing rights that remain partially unresolved.

A separate thread of litigation involved Arrowhead Pharmaceuticals, which challenged certain Alnylam patents related to RNA interference trigger molecules. While this litigation did not name inclisiran directly, the outcomes affected the enforceability of foundational IP that underpins the drug's delivery mechanism. Court decisions in the U.S. District Court for the District of Delaware between 2018 and 2021 narrowed some Alnylam claims but upheld others, leaving the core GalNAc conjugate patents intact.

For clinicians, the practical takeaway is this: inclisiran's composition-of-matter patents are expected to provide market exclusivity into the mid-2030s. No abbreviated new drug application (ANDA) pathway exists for siRNA biosimilars under current FDA guidance, meaning generic competition is unlikely before 2036 at the earliest. The Biologics Price Competition and Innovation Act (BPCIA) governs the biosimilar pathway for biological products, but the FDA has not yet approved any siRNA biosimilar, and the regulatory framework for demonstrating analytical similarity of siRNA conjugates remains undefined.

The Label: Narrower Than Expected

Novartis sought a broad cardiovascular risk-reduction indication. What the FDA granted was narrower. The approved label restricts Leqvio to patients with established ASCVD or HeFH who need additional LDL-C lowering as an adjunct to maximally tolerated statin therapy (Leqvio prescribing information, FDA). The label does not include a cardiovascular outcomes claim.

This distinction matters. PCSK9 monoclonal antibodies like evolocumab (Repatha) and alirocumab (Praluent) earned cardiovascular outcomes data from FOURIER (N=27,564) and ODYSSEY OUTCOMES (N=18,924), respectively. Those trials demonstrated reductions in major adverse cardiovascular events (MACE). Inclisiran's ORION-4 outcomes trial (N=15,000, estimated completion 2026) has not yet reported results (ORION-4, ClinicalTrials.gov).

Without a MACE reduction claim on the label, payers and formulary committees treat Leqvio differently from the monoclonal PCSK9 inhibitors. Dr. Steven Nissen, Chief Academic Officer of the Heart, Vascular, and Thoracic Institute at Cleveland Clinic, stated in a 2022 commentary: "Inclisiran lowers LDL impressively, but until ORION-4 reads out, we are extrapolating cardiovascular benefit from the LDL hypothesis rather than proving it directly with this specific molecule."

The label also carries a specific warning about injection-site reactions, which occurred at higher rates than placebo in the ORION trials. While these reactions were overwhelmingly mild (Grade 1), their presence on the label has provided ammunition for prior authorization requirements by commercial insurers.

Medicare Part B Reimbursement: An Unusual Drug in an Unusual Channel

Most cholesterol-lowering drugs flow through Medicare Part D (pharmacy benefit). Leqvio is different. Because it is administered by a healthcare professional via subcutaneous injection every six months, CMS classified it under Medicare Part B (medical benefit, buy-and-bill model). This classification created both opportunities and obstacles.

The opportunity: Part B drugs face fewer formulary restrictions than Part D drugs, and patients typically pay a 20% coinsurance rather than navigating tiered copays. The obstacle: physician offices must purchase the drug upfront and seek reimbursement from CMS, which introduces cash-flow risk.

CMS initially set the average sales price (ASP) reimbursement at ASP + 6%, consistent with standard Part B drug reimbursement. But the list price of Leqvio (approximately $3,250 per injection, or $6,500 per year) triggered scrutiny from the CMS Innovation Center, which explored including inclisiran in value-based payment models. The Inflation Reduction Act's drug price negotiation provisions, effective for certain Part B and Part D drugs beginning in 2026, could also affect Leqvio's reimbursement trajectory, though CMS has not yet named inclisiran among the first cohorts selected for negotiation (CMS IRA implementation guidance).

In practice, the buy-and-bill model has slowed U.S. uptake. A 2023 analysis published in JAMA Network Open found that fewer than 50,000 Medicare beneficiaries received Leqvio in its first full year of commercial availability, compared to the millions of ASCVD patients who might be clinically eligible (Zhang et al., JAMA Netw Open 2023). Cardiology practices cited reimbursement uncertainty and prior authorization burden as the top barriers.

Post-Market Safety Surveillance

The FDA required Novartis to conduct several post-marketing studies as conditions of approval. These include:

ORION-4 (cardiovascular outcomes trial): This double-blind, randomized, placebo-controlled trial enrolled approximately 15,000 participants with ASCVD across 180 sites in the UK and the U.S. Primary endpoint is time to first occurrence of a major coronary event (coronary heart disease death, myocardial infarction, or urgent coronary revascularization). Results are anticipated by late 2026.

ORION-8 (long-term open-label extension): This study evaluates safety and efficacy of inclisiran beyond three years, with participants rolling over from ORION-5, -9, -10, and -11. Interim data through 4 years showed sustained LDL-C reductions of approximately 48% with no new safety signals, though platelet count decreases of uncertain clinical significance were noted in a small subset (Ray et al., ESC 2023 presentation).

FDA Sentinel System monitoring: The FDA's Sentinel active surveillance system is tracking inclisiran for signals related to hepatotoxicity, immune-mediated reactions, and injection-site complications in the real-world population. Because siRNA therapies are a relatively new drug class, the agency flagged theoretical risks related to off-target gene silencing and accumulation in non-hepatic tissues, although no clinical evidence of either has materialized.

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has separately required Novartis to submit periodic safety update reports (PSURs) at six-month intervals, a more frequent cadence than the standard annual requirement, reflecting the novelty of the siRNA mechanism.

Litigation Risks Beyond Patents

Patent disputes are not the only legal exposure. Three additional categories of litigation risk deserve attention.

Product liability: As of mid-2026, no major product liability lawsuits have been filed against Leqvio. But the injection-site reaction profile and the theoretical concern about long-term hepatic siRNA accumulation create latent exposure. Any future signal from ORION-4 or Sentinel monitoring could change this calculus rapidly.

Off-label promotion: The gap between Leqvio's label (LDL reduction) and its marketed value proposition (cardiovascular risk reduction) creates regulatory risk under the False Claims Act. Novartis has publicly maintained that its promotional materials stay within the approved indication, but the Department of Justice has historically scrutinized drugs where the clinical narrative outpaces the label. Novartis paid $678 million in 2020 to resolve kickback allegations related to other cardiovascular drugs, which increases DOJ attention on the company's cardiovascular franchise (DOJ press release, 2020).

Antitrust and access: Patient advocacy groups have raised concerns about the interaction between Leqvio's patent protection, its buy-and-bill reimbursement model, and patient access. A 2024 letter from the National Lipid Association to CMS argued that the Part B classification, combined with prior authorization requirements imposed by Medicare Advantage plans, created de facto access barriers for the highest-risk patients who stand to benefit most (NLA position statement, 2024).

How Inclisiran's Regulatory Position Compares to PCSK9 Monoclonal Antibodies

Evolocumab (Repatha) and alirocumab (Praluent) provide useful reference points. Both received FDA approval in 2015, initially with LDL-reduction-only labels. Amgen (Repatha) obtained a supplemental cardiovascular outcomes claim in December 2017 based on FOURIER data. Sanofi/Regeneron (Praluent) followed with ODYSSEY OUTCOMES data in 2018.

The patent history of PCSK9 monoclonals is instructive. Amgen and Sanofi/Regeneron engaged in a protracted patent dispute over antibody claims to PCSK9, with Amgen ultimately prevailing at the Federal Circuit in 2021. That litigation constrained Praluent's U.S. market position for years. Inclisiran, as an siRNA rather than an antibody, sidesteps the PCSK9 antibody patent thicket entirely, but it inherits a different and equally complex set of IP constraints from the Alnylam platform.

Price competition is another differentiator. List prices for Repatha and Praluent have dropped substantially from their 2015 launch prices (Repatha from $14,100 to approximately $5,850 per year; Praluent similarly). Leqvio's $6,500 annual cost is competitive, but the buy-and-bill model creates friction that self-administered subcutaneous injectables (Repatha, Praluent) avoid.

"The irony of inclisiran is that its greatest clinical advantage, twice-yearly dosing, is also its greatest commercial obstacle," noted Dr. Harlan Krumholz, Harold H. Hines Jr. Professor of Medicine at Yale School of Medicine. "A drug that patients don't need to remember to take still needs a healthcare system that remembers to give it."

What Clinicians Should Watch in 2026 and 2027

Three events will shape Leqvio's regulatory and legal trajectory over the next 18 months.

First, the ORION-4 readout. A positive cardiovascular outcomes result would support a supplemental label claim, shift payer behavior, and substantially reduce off-label promotion risk. A neutral or negative result would raise fundamental questions about the LDL hypothesis as applied to siRNA-mediated PCSK9 silencing versus protein-level PCSK9 inhibition.

Second, CMS drug price negotiation decisions. If inclisiran is selected for negotiation under the Inflation Reduction Act in a future cohort, the negotiated price could alter the buy-and-bill economics for physician practices.

Third, the Alnylam patent portfolio. Several key patents face inter partes review challenges at the Patent Trial and Appeal Board. Decisions expected in 2027 could narrow or affirm the scope of protection, directly affecting Novartis's exclusivity timeline and any potential biosimilar entry pathway.

Clinicians prescribing Leqvio today should document the clinical rationale for each patient (established ASCVD or confirmed HeFH, inadequate response to maximally tolerated statin therapy), ensure the prior authorization submission references the FDA-approved indication verbatim, and track injection-site reactions per the REMS-like monitoring that many institutions have adopted voluntarily. The median LDL-C reduction of 50% at steady state, confirmed across ORION-9, -10, and -11, remains the strongest evidence basis for prescribing decisions until ORION-4 delivers outcomes data (Ray et al., NEJM 2020).